BCR and Waldenstrom macroglobulinemia: In line with these findings, in Waldenström macroglobulinemia and DLBCL human cell lines, inactivation of TNFAIP3 (encoding A20, a negative regulator of NF-κB signaling) also cooperates with MYD88LP mutation to enhance NF-κB activation and resistance to BCR signaling inhibitor, ibrutinib65,66.